Anaerobic PerformanceSleepCrMNCT06937190
Pre-Sleep Creatine Enhances Anaerobic Power in Recreationally Active Females
A study testing Creatine Monohydrate in people with Anaerobic Performance and Sports Nutrition, run by Ankara Yildirim Beyazıt University at 1 site in Iran.
Trial summary
This study is a randomized, double-blind, placebo-controlled trial designed to examine the effects of pre-sleep creatine monohydrate supplementation on anaerobic performance and muscle damage markers in recreationally active females. Read more about this study
- Who is it for?
- Ages 18 to 25 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Anaerobic Performance, Sports Nutrition, Exercise Recovery
- What is being tested?
- Creatine Monohydrate
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 24 participants
- Where
- 1 siteIran
- Study dates
- 1 Apr 2025to 10 Jul 2025
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 25 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Female, aged 18 to 25 years
- Recreationally active (engaging in structured resistance training 3-4 times per week for the past 6 months)
- Regular menstrual cycles (used for scheduling purposes)
- Able and willing to provide informed consent
- Agreement to maintain normal diet and training routines throughout the study
Who cannot join
- History of musculoskeletal injury affecting lower or upper limbs within the past 6 months
- Known allergy or intolerance to creatine or maltodextrin
- Use of performance-enhancing substances or supplements within the last 30 days
- Use of recovery modalities such as massage, cryotherapy, or compression garments during the study period
- Current use of anti-inflammatory medication
- Pregnancy or breastfeeding
- Inability to comply with study protocol or scheduled assessments
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Iran1 site, 1 recruiting
- Recruiting
Islamic Azad University, Shabestar Branch
Shabestar, East Azerbaijan Province, 5381637183
Morteza Jourkesh, PhD, +98 938 278 4093, mjourkesh@iau.ac.ir
About this study
This study is a randomized, double-blind, placebo-controlled trial designed to examine the effects of pre-sleep creatine monohydrate supplementation on anaerobic performance and muscle damage markers in recreationally active females. Participants will be randomly assigned to receive either 5 grams of creatine monohydrate or a placebo 30 minutes before sleep for seven consecutive days. Anaerobic performance will be assessed using the Wingate Anaerobic Test, evaluating peak and average power output and fatigue index. Blood samples will be collected before and after the supplementation period to analyze markers of muscle damage, including creatine kinase and lactate dehydrogenase. This study aims to provide insight into the efficacy of short-term, time-specific creatine supplementation for enhancing performance and recovery.
- Conditions
- Anaerobic Performance, Sports Nutrition, Exercise Recovery, Muscle Fatigue, Creatine Supplementation, Recreational Physical Activity
- Being tested
- Creatine Monohydrate, Placebo (Maltodextrin)
- Keywords
- Creatine Monohydrate, Pre-Sleep Supplementation, Anaerobic Power, Wingate Test, Muscle Damage Markers, Creatine Kinase (CK), Lactate Dehydrogenase (LDH), Female Exercise Performance, Nutritional Ergogenic Aid, Resistance Training, Recovery Enhancement
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Creatine MonohydrateDietary supplement
Participants will receive 5 grams of creatine monohydrate powder dissolved in water, flavored with a sugar-free agent, 30 minutes before sleep each night for 7 days.
Placebo (Maltodextrin)Dietary supplement
Visually identical placebo (maltodextrin powder, 5 g/day), flavored with a sugar-free agent, dissolved in water and consumed 30 minutes before sleep for 7 consecutive days.
| Study group | Role | What they receive |
|---|---|---|
| Creatine Monohydrate Supplementation | Experimental | Participants will receive 5 grams of creatine monohydrate powder dissolved in water, flavored with a sugar-free agent, 30 minutes before sleep each night for 7 days. Receives: Dietary Supplement: Creatine Monohydrate |
| Placebo Supplementation | Placebo comparator | Participants will receive 5 grams of a placebo powder (maltodextrin), visually identical and similarly flavored to the creatine supplement, 30 minutes before sleep each night for 7 days. Receives: Dietary Supplement: Placebo (Maltodextrin) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Average Power Output (Watts) - 30-Second Wingate Test
Average anaerobic power output will be calculated across the 30-second Wingate cycling test.
Measured: Baseline and post-intervention (Day 0 and Day 7)
Secondary outcomes (4)
Peak Power Output (Watts) - Wingate Test
Peak power output during the initial 5 seconds of the 30-second Wingate cycling test.
Measured: Baseline and post-intervention (Day 0 and Day 7)
Fatigue Index (%) - Wingate Test
Calculated as the percent drop in power from peak to minimum power output during the 30-second Wingate test, indicating fatigue rate.
Measured: Baseline and post-intervention (Day 0 and Day 7)
Serum Creatine Kinase (CK) Activity
Serum creatine kinase activity will be measured as a marker of muscle damage using a spectrophotometric assay.
Measured: Baseline and 24 hours post Wingate Test (Day 0 and Day 8)
Serum Lactate Dehydrogenase (LDH) Activity
Serum lactate dehydrogenase activity will be measured as an indicator of cell membrane permeability and muscle damage using spectrophotometry.
Measured: Baseline and 24 hours post Wingate Test (Day 0 and Day 8)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Apr 2025
- Study start1 Apr 2025
- Primary completion10 May 2025 (estimated)
- Study completion10 Jul 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Anaerobic PerformanceStudies of the same condition, open and under way.
- More trials run by Ankara Yildirim Beyazıt UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants are randomly assigned to one of two groups: a creatine supplementation group or a placebo group, and they remain in that group for the duration of the trial.
- Masking
- None (open label)
- Enrolment
- 24 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ankara Yildirim Beyazıt University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, caglar soylu, Ankara Yildirim Beyazıt University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06937190
- Sponsor's protocol ID
- 162593019
- Acronym
- SleepCrM
- Status last verified
- Apr 2025
- First submitted
- 15 Apr 2025
- Last updated
- 22 Apr 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The individual participant data (IPD) will not be shared due to privacy concerns and the limited scope of this study. The study involves a small sample size, and data sharing could risk participant confidentiality. Additionally, there are currently no external collaborations or repositories arranged for data sharing.
Study at a glance
From the registry record, last updated by the sponsor on 22 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pre-Sleep Creatine Enhances Anaerobic Power in Recreationally Active Females
- ClinicalTrials.gov ID
- NCT06937190
- Acronym / sponsor ID
- SleepCrM / 162593019
- Conditions
- Anaerobic Performance, Sports Nutrition, Exercise Recovery, Muscle Fatigue, Creatine Supplementation, Recreational Physical Activity
- Keywords
- Creatine Monohydrate, Pre-Sleep Supplementation, Anaerobic Power, Wingate Test, Muscle Damage Markers, Creatine Kinase (CK), Lactate Dehydrogenase (LDH), Female Exercise Performance
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 24 participants (estimated)
- Lead sponsor
- Ankara Yildirim Beyazıt UniversityUniversity, hospital or other
- Study start
- 1 Apr 2025 (actual)
- Primary completion
- 10 May 2025 (estimated)
- Study completion
- 10 Jul 2025 (estimated)
- First posted
- 22 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a randomized, double-blind, placebo-controlled trial designed to examine the effects of pre-sleep creatine monohydrate supplementation on anaerobic performance and muscle damage markers in recreationally active females. Participants will be randomly assigned to receive either 5 grams of creatine monohydrate or a placebo 30 minutes before sleep for seven consecutive days. Anaerobic performance will be assessed using the Wingate Anaerobic Test, evaluating peak and average power output and fatigue index. Blood samples will be collected before and after the supplementation period to analyze markers of muscle damage, including creatine kinase and lactate dehydrogenase. This study aims to provide insight into the efficacy of short-term, time-specific creatine supplementation for enhancing performance and recovery.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Participants are randomly assigned to one of two groups: a creatine supplementation group or a placebo group, and they remain in that group for the duration of the trial.
| Arm | Type | Receives |
|---|---|---|
| Creatine Monohydrate Supplementation | Experimental | Dietary Supplement: Creatine MonohydrateParticipants will receive 5 grams of creatine monohydrate powder dissolved in water, flavored with a sugar-free agent, 30 minutes before sleep each night for 7 days. |
| Placebo Supplementation | Placebo comparator | Dietary Supplement: Placebo (Maltodextrin)Participants will receive 5 grams of a placebo powder (maltodextrin), visually identical and similarly flavored to the creatine supplement, 30 minutes before sleep each night for 7 days. |
Who may qualify
- Ages
- 18 to 25 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Female, aged 18 to 25 years
- Recreationally active (engaging in structured resistance training 3-4 times per week for the past 6 months)
- Regular menstrual cycles (used for scheduling purposes)
- Able and willing to provide informed consent
- Agreement to maintain normal diet and training routines throughout the study
Key exclusion criteria (7 listed)
- History of musculoskeletal injury affecting lower or upper limbs within the past 6 months
- Known allergy or intolerance to creatine or maltodextrin
- Use of performance-enhancing substances or supplements within the last 30 days
- Use of recovery modalities such as massage, cryotherapy, or compression garments during the study period
- Current use of anti-inflammatory medication
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Creatine MonohydrateParticipants will receive 5 grams of creatine monohydrate powder dissolved in water, flavored with a sugar-free agent, 30 minutes before sleep each night for 7 days. | Dietary supplement | Creatine Monohydrate Supplementation |
| Placebo (Maltodextrin)Visually identical placebo (maltodextrin powder, 5 g/day), flavored with a sugar-free agent, dissolved in water and consumed 30 minutes before sleep for 7 consecutive days. | Dietary supplement | Placebo Supplementation |
Primary outcome
Average Power Output (Watts) - 30-Second Wingate Test
Time frame: Baseline and post-intervention (Day 0 and Day 7)
Average anaerobic power output will be calculated across the 30-second Wingate cycling test.
4 secondary outcomes
Peak Power Output (Watts) - Wingate Test
Time frame: Baseline and post-intervention (Day 0 and Day 7)
Fatigue Index (%) - Wingate Test
Time frame: Baseline and post-intervention (Day 0 and Day 7)
Serum Creatine Kinase (CK) Activity
Time frame: Baseline and 24 hours post Wingate Test (Day 0 and Day 8)
Serum Lactate Dehydrogenase (LDH) Activity
Time frame: Baseline and 24 hours post Wingate Test (Day 0 and Day 8)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Apr 2025.
- Individual participant dataSharing planned: No. The individual participant data (IPD) will not be shared due to privacy concerns and the limited scope of this study. The study involves a small sample size, and data sharing could risk participant confidentiality. Additionally, there are currently no external collaborations or repositories arranged for data sharing.
Related trials for Anaerobic Performance
Not yet recruitingObservational study
Isokinetic Knee Strength, Bilateral Muscle Balance, and Anaerobic Performance in Adolescent Athletes
Isokinetic Knee Strength, Hamstring-to-Quadriceps Strength Ratio
Active, not recruiting
Effects of Blood Flow Restriction Training on Physical Function, Muscle Adaptations, and Performance in Roller Skaters
Athletic Performance Enhancement
Not yet recruitingObservational study
Pulmonary Function and Trunk Muscle Performance in Wrestlers
Pulmonary Function, Aerobic Performance
Not yet recruiting
SJFT Performance, Inhibitory Control, and Attention in Young Judokas
Cognitive Performance, Inhibitory Control
Not yet recruitingObservational study
Respiratory Muscle Strength and Jiu-Jitsu-Specific Performance in Male Brazilian Jiu-Jitsu Athletes
Athletic Performance
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Creatine Monohydrate in people with Anaerobic Performance and Sports Nutrition, run by Ankara Yildirim Beyazıt University at 1 site in Iran.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 22 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Iran. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Morteza Jourkesh, PhD (+98 938 278 4093, mjourkesh@iau.ac.ir), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Average Power Output (Watts) - 30-Second Wingate Test (time frame: Baseline and post-intervention (Day 0 and Day 7)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Apr 2025.